Last 31 quarters of trend data · Healthcare · Medical - Healthcare Information Services
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -99.30 | — | — | — | 10.34 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.86 | 4.51 | 3.12 | 2.46 | 2.08 | 1.73 | 2.65 | 4.49 | 3.81 | 7.94 | 9.02 | 7.90 | 11.10 |
| — | +161.3% | +18.0% | -45.2% | -45.3% | -78.3% | -70.7% | -43.1% | -65.6% | -33.8% | +34.7% | +27.5% | -1.0% | |
| P/B Ratio | 5.44 | 3.34 | 2.60 | 1.87 | 1.86 | 1.51 | 2.46 | 3.77 | 3.23 | 6.23 | 8.95 | 6.52 | 8.21 |
| — | +120.9% | +5.9% | -50.5% | -42.2% | -75.7% | -72.5% | -42.1% | -60.7% | -22.5% | +72.5% | +55.6% | +25.2% | |
| P/FCF | 33.91 | 27.77 | 13.29 | 8.62 | 22.35 | 8.24 | — | 38.39 | 161.37 | — | 74.36 | — | — |
| — | +236.8% | — | -77.5% | -86.2% | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | 7.11 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 7.64 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
10x Genomics, Inc.'s operating margin was -11.3% in Q1 2026, up 0.5 pp QoQ and up 14.1 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -6.8% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 3.4% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.1% | 70.4% | 68.1% | 67.3% | 72.3% | 68.1% | 67.2% | 70.2% | 68.1% | 65.9% | 62.9% | 62.2% | 67.8% |
| — | +3.4% | +1.3% | -4.0% | +6.3% | +3.3% | +6.8% | +12.8% | +0.3% | -10.1% | -17.7% | -19.1% | -10.5% | |
| Operating Margin | -17.2% | -11.3% | -11.8% | -21.6% | 17.4% | -25.4% | -30.2% | -27.4% | -27.3% | -43.6% | -30.0% | -61.7% | -43.2% |
| — | +55.5% | +61.0% | +20.9% | +163.9% | +41.8% | -0.7% | +55.7% | +36.8% | -12.7% | -102.9% | -102.2% | +21.6% | |
| Net Margin | -6.8% | -8.9% | -9.8% | -18.4% | 20.0% | -22.2% | -29.7% | -23.6% | -24.8% | -42.5% | -26.6% | -60.5% | -42.5% |
| — | +59.7% | +67.1% | +21.8% | +180.7% | +47.8% | -11.7% | +61.0% | +41.8% | -12.5% | -141.5% | -89.3% | +24.4% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -5.8% | -1.7% | -2.1% | -3.5% | 4.7% | -4.8% | -6.8% | -4.9% | -5.3% | -8.2% | -6.6% | -12.1% | -7.8% |
| — | +65.5% | +70.0% | +28.7% | +188.8% | +41.0% | -3.9% | +59.1% | +32.9% | -30.1% | -202.6% | -124.8% | +3.5% | |
| ROA | -4.4% | -1.3% | -1.6% | -2.7% | 3.7% | -3.8% | -5.3% | -3.8% | -4.1% | -6.4% | -5.1% | -9.6% | -6.2% |
| — | +65.3% | +70.3% | +28.5% | +189.6% | +40.6% | -3.2% | +60.1% | +34.3% | -27.8% | -200.9% | -128.7% | +3.1% | |
| ROIC | -17.9% | -2.9% | -2.9% | -4.9% | 5.2% | -6.9% | -8.7% | -7.4% | -7.0% | -9.9% | -8.2% | -12.9% | -8.3% |
| — | +58.0% | +66.2% | +32.9% | +173.6% | +30.6% | -6.1% | +43.0% | +15.6% | -59.0% | -212.2% | -168.7% | -6.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 9.7% YoY to 5.90x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.10 | 0.20 | 0.21 | 0.11 | 0.11 | 0.12 | 0.12 | 0.12 | 0.13 | 0.13 | 0.13 | 0.13 |
| — | -11.8% | +70.3% | +75.2% | -9.2% | -11.7% | -9.6% | -10.1% | -1.6% | +0.8% | +9.0% | +6.5% | -0.6% | |
| Debt / EBITDA | — | — | — | — | 2.18 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.46 | 5.90 | 4.46 | 4.48 | 5.84 | 5.37 | 4.97 | 4.90 | 5.22 | 5.22 | 4.69 | 5.37 | 5.94 |
| — | +9.7% | -10.2% | -8.6% | +12.0% | +3.0% | +6.0% | -8.8% | -12.2% | -2.9% | -3.3% | +8.2% | +5.2% | |
| Quick Ratio | 4.09 | 5.42 | 4.09 | 4.06 | 5.23 | 4.68 | 4.26 | 4.12 | 4.42 | 4.45 | 4.11 | 4.60 | 5.09 |
| — | +15.9% | -3.9% | -1.6% | +18.2% | +5.2% | +3.7% | -10.3% | -13.1% | -4.1% | -2.8% | +5.9% | +0.8% | |
| Interest Coverage | — | — | — | -9400.67 | 12333.33 | — | — | -17218.00 | -37078.00 | -57802.00 | -5823.75 | -91743.00 | -12152.40 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 31 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TXG stock.
10x Genomics, Inc.'s current P/E is -99.3x. The average P/E over the last 1 quarters is 10.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
10x Genomics, Inc.'s current operating margin is -17.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking 10x Genomics, Inc.'s business trajectory between earnings reports.